PT  - JOURNAL ARTICLE
AU  - ,
AU  - Buck, Michael D.
AU  - Poirier, Enzo Z.
AU  - Cardoso, Ana
AU  - Frederico, Bruno
AU  - Canton, Johnathan
AU  - Barrell, Sam
AU  - Beale, Rupert
AU  - Byrne, Richard
AU  - Caidan, Simon
AU  - Crawford, Margaret
AU  - Cubitt, Laura
AU  - Gamblin, Steve
AU  - Gandhi, Sonia
AU  - Goldstone, Robert
AU  - Grant, Paul R.
AU  - Gulati, Kiran
AU  - Hindmarsh, Steve
AU  - Howell, Michael
AU  - Hubank, Michael
AU  - Instrell, Rachael
AU  - Jiang, Ming
AU  - Kassiotis, George
AU  - Lu, Wei-Ting
AU  - MacRae, James I.
AU  - Martini, Iana
AU  - Miller, Davin
AU  - Moore, David
AU  - Nastouli, Eleni
AU  - Nicod, Jerome
AU  - Nightingale, Luke
AU  - Olsen, Jessica
AU  - Oomatia, Amin
AU  - O’Reilly, Nicola
AU  - Rideg, Anett
AU  - Song, Ok-Ryul
AU  - Strange, Amy
AU  - Swanton, Charles
AU  - Turajlic, Samra
AU  - Walker, Philip A.
AU  - Wu, Mary
AU  - Sousa, Caetano Reis e
TI  - Standard operating procedures for SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay
AID  - 10.1101/2020.06.29.20142430
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20142430
4099  - http://medrxiv.org/content/early/2020/07/01/2020.06.29.20142430.short
4100  - http://medrxiv.org/content/early/2020/07/01/2020.06.29.20142430.full
AB  - The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical research institute, in collaboration between partner hospitals and an accredited clinical diagnostic laboratory, established a diagnostic testing pipeline that has reported on more than 40,000 RT-qPCR results since its commencement at the beginning of April 2020. However, due to ongoing demand and competition for critical resources, alternative testing strategies were sought. In this work, we present a clinically-validated standard operating procedure (SOP) for high-throughput SARS-CoV-2 detection by RT-LAMP in 25 minutes that is robust, reliable, repeatable, sensitive, specific, and inexpensive.Competing Interest StatementD. Miller and K. Gulati are employees of New England Biolabs, which provided the WarmStart Colorimetric LAMP 2X Master Mix used in this work. C. Swanton receives or has received grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb (BMS), Roche-Ventana, Boehringer-Ingelheim, and Ono Pharmaceutical and has consulted for or received an honorarium from Pfizer, Novartis, GlaxoSmithKline, Merck Sharp & Dohme, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Venatana, GRAIL, Medicxi, and the Sarah Cannon Research Institute. C. Swanton also is a shareholder of Apogen Biotechnologies, Epic Bioscience, and GRAIL and has stock options in and is a cofounder of Achilles Therapeutics.Clinical Protocols https://www.crick.ac.uk/research/covid-19/covid19-consortium Funding StatementThis work was supported by The Rosetrees Trust and The John Black Charitable Foundation, as well as the Francis Crick Institute, which receives its funding from the UK Research Medical Council (FC001169, FC001078), Cancer Research UK (FC001169, FC001078) and the Wellcome Trust (FC001169, FC001078). E. Nastouli is funded by MRC, NIHR, GSK and H2020. S. Gandhi has an MRC Senior Clinical Fellowship. E.Z. Poirier and M.D. Buck are supported by EMBO Long-Term Fellowships (ALTF 536-2108 and ALTF 1096-2018) and Marie Skłodowska-Curie Individual Fellowships (832511 and 837951).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Crick COVID-19 Consortium (CCC) was formed in partnership with HSL, a UCLH UKAS accredited lab, who already had a COVID-19 RT-qPCR test in scope. All samples were received and communicated by HSL under their accreditation and the CCC RT-LAMP assay was validated against their existing RT-qPCR test and the CCC validated RT-qPCR test, which uses a CE marked commercial kit (BGI). Given the urgent timeframe required to implement testing, it was not possible to secure official clinical laboratory accreditation for the Francis Crick Institute. However, full measures were taken to ensure that the CCC RT-LAMP test was evaluated, verified and performed for diagnostic use in an environment that adhered to equivalent international standards (ISO 15189:2012, US equiv. CAP/CLIA), overseen and audited by HSL. These measures were implemented under the advice and oversight of registered professionals from existing nearby ISO accredited medical laboratories, and included writing and following clinical diagnostic SOPs for every stage of the pipeline from sample reception, processing to result reporting by qualified clinical scientists prior to results being communicated to patients by HSL. Additional SOPs were followed for sample storage, disposal of materials, batch certification of reagents and incident reporting. Appropriate risk assessments, training and competency assessment procedures were established and documented. Record sheets were created to document the receipt, batch acceptance testing, and start/end of use dates for key reagents and consumables. An inventory of all key equipment was compiled which, where appropriate, included details of service and calibration records. Systems were also established for the control of all key documents (version implementation, distribution and acknowledgement), audit trailing (what samples were tested when, by whom, with what equipment and using which consumable/reagent batches), and the recording of all untoward incidents/issues (thus facilitating appropriate investigation, rectification and recurrence prevention). Samples were barcoded and tracked using the Crick Clarity library information management system (LIMS). All key documents are available at https://www.crick.ac.uk/research/covid-19/covid19-consortium. NHS governance was extended by a specific memorandum of understanding for diagnostic testing between UCLH and the Francis Crick Institute enabled by NHS England. Assurance of the pipeline was performed in collaboration with GenQA, following their checklist for non-accredited laboratories and the lab and CCC workflow were inspected by a qualified UKAS assessor against the GenQA guidelines to verify compliance to IS015189:2012 equivalent standard.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll key documents are available at https://www.crick.ac.uk/research/covid-19/covid19-consortium https://www.crick.ac.uk/research/covid-19/covid19-consortium